Dr. Garcia-Manero on Targeting IRAK4 in MDS

By Cecilia Brown, Guillermo Garcia-Manero, MD - Last Updated: February 8, 2024

Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, discusses a phase 1b clinical study that evaluated IRAK1/4 inhibition in patients with low-risk myelodysplastic syndromes that are refractory or resistant to prior therapies.

Advertisement

Dr. Garcia-Manero presented information about the study’s design and enrollment process during the 2023 American Society of Clinical Oncology Annual Meeting.

Post Tags:ASCO2023
Advertisement
Advertisement
Advertisement
Editorial Board